HAMILTON, BERMUDA, July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue Under the terms of the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the ...
CILA’s proprietary, gene-agnostic platform, CIL-Key™, is designed to enable the development of breakthrough inhaled RNA therapeutics and vaccines for pulmonary diseases — potentially unlocking new ...
Lexeo Therapeutics partners for $40 million investment to develop RNA-based therapies for genetic cardiac diseases using non-viral delivery technology. Lexeo Therapeutics, Inc. announced a strategic ...
With the question of immunotherapeutics’ efficacy answered in the resounding affirmative, the challenge has shifted to the practical considerations of how to cost-effectively manufacture these highly ...
What keeps our cells the right size? Scientists have long puzzled over this fundamental question, since cells that are too large or too small are linked to many diseases. Until now, the genetic basis ...
ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...
Many essential biochemical processes in cells in various life forms involve RNA molecules, which are critical for development, proliferation, homeostasis, immune defense, intercellular communication, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback